B3GALNT2 is a UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 (EC 2.4.1.313), a type II single-pass membrane glycosyltransferase of the GT31 (beta-1,3-glycosyltransferase) family. It transfers N-acetylgalactosamine (GalNAc) from UDP-GalNAc in a beta-1,3 linkage onto a terminal beta-linked N-acetylglucosamine (GlcNAc), producing the disaccharide GalNAc-beta1-3-GlcNAc. Its principal physiological role is in the elongation of the O-mannosyl glycan of alpha-dystroglycan (DAG1): acting immediately after POMGNT2 (which adds beta-1,4-GlcNAc to protein O-mannose), B3GALNT2 caps the chain with beta-1,3-GalNAc to form the core M3 trisaccharide GalNAc-beta3-GlcNAc-beta4-mannose. This trisaccharide is the obligate substrate for 6-O-phosphorylation of the mannose by POMK and for subsequent extension by FKTN, FKRP, RXYLT1, B4GAT1 and LARGE into matriglycan, the polysaccharide that mediates high-affinity binding of alpha-dystroglycan to laminin-G domain-containing extracellular matrix proteins. In addition to this O-mannosyl glycan, B3GALNT2 can synthesize the same type-I LacdiNAc (GalNAc-beta1,3-GlcNAc) disaccharide on the N-glycans of mainly intracellular glycoproteins, although the physiological significance of this broader activity is not yet established. The enzyme is broadly expressed (highest in testis, adipose, skeletal muscle and ovary) and localizes mainly to the endoplasmic reticulum and partly to the Golgi apparatus. Biallelic loss-of-function mutations cause hypoglycosylation of alpha-dystroglycan and a congenital muscular dystrophy-dystroglycanopathy (MDDGA11), ranging from Walker-Warburg syndrome to milder muscle-eye-brain phenotypes.
Definition: Catalysis of the transfer of an N-acetylgalactosaminyl residue from UDP-N-acetyl-D-galactosamine to the 3-position of the beta-1,4-linked N-acetylglucosamine of a protein O-linked mannosyl glycan, forming a beta-1,3 glycosidic bond and producing the GalNAc-beta1,3-GlcNAc-beta1,4-mannose (core M3) trisaccharide. EC 2.4.1.313.
Justification: The existing MF term GO:0008376 (acetylgalactosaminyltransferase activity) is defined as transfer of GalNAc to an oligosaccharide and is broader than the physiologically relevant reaction. There is no GO term specific to the protein-O-mannose-glycan acceptor / EC 2.4.1.313 reaction that B3GALNT2 performs in alpha-dystroglycan core M3 biosynthesis (a gap flagged by the RHEA-GO project). A child of GO:0008376 grounded on RHEA:37667 / EC 2.4.1.313 would let B3GALNT2 be annotated to its exact catalytic activity.
Parent term: acetylgalactosaminyltransferase activity
Mappings:
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
|
GO:0000139
Golgi membrane
|
IBA
GO_REF:0000033 |
KEEP AS NON CORE |
Summary: Golgi membrane is the GT31-family default location inferred phylogenetically. B3GALNT2 is a type II membrane glycosyltransferase and many family members are Golgi-resident, so this is biologically plausible. However, for the experimentally characterized alpha-dystroglycan function the enzyme is shown to act in the endoplasmic reticulum, where O-mannosylation and core M3 assembly occur. Independent glycoproteomic work (Nakane et al. 2019, PMID:30898876) concurs that B3GALNT2 "mainly localizes in the ER and partly in the Golgi apparatus", supporting the keep-as-non-core call for the Golgi membrane location. Keep as a plausible secondary location but not the core experimentally supported compartment.
Supporting Evidence:
PMID:30898876
B3GALNT2 mainly localizes in the ER and partly in the Golgi apparatus
file:human/B3GALNT2/B3GALNT2-deep-research-falcon.md
primary experimental evidence more strongly supports ER localization for active B3GALNT2
|
|
GO:0006493
protein O-linked glycosylation
|
IBA
GO_REF:0000033 |
MODIFY |
Summary: Correct in direction but unspecific. B3GALNT2's characterized biological role is specifically the elongation of the protein O-mannosyl (core M3) glycan of alpha-dystroglycan. The more precise child term "protein O-linked glycosylation via mannose" (GO:0035269) better captures the actual O-mannosyl pathway rather than generic O-linked (e.g. mucin-type O-GalNAc) glycosylation.
Proposed replacements:
protein O-linked glycosylation via mannose
|
|
GO:0008194
UDP-glycosyltransferase activity
|
IBA
GO_REF:0000033 |
MODIFY |
Summary: Not wrong (the enzyme uses a UDP-sugar donor) but over-general. The experimentally established activity is the specific acetylgalactosaminyltransferase activity (GO:0008376, supported by IDA in PMID:23929950 and biochemical characterization in PMID:14724282). This broad parent term should be replaced by the specific activity.
Proposed replacements:
acetylgalactosaminyltransferase activity
|
|
GO:0000139
Golgi membrane
|
IEA
GO_REF:0000044 |
KEEP AS NON CORE |
Summary: Electronic mapping from the UniProt subcellular-location keyword (Golgi apparatus membrane, by similarity). Same content as the IBA Golgi annotation; biologically plausible family default but secondary to the experimentally supported ER localization for the alpha-DG function.
|
|
GO:0005783
endoplasmic reticulum
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: Electronic mapping consistent with the experimental IDA localization (PMID:23453667), where B3GALNT2 was shown to localize to the ER and disease missense variants perturb this localization. Accept.
|
|
GO:0009101
glycoprotein biosynthetic process
|
IEA
GO_REF:0000120 |
MODIFY |
Summary: Over-general process annotation derived from the InterPro glycosyltransferase family. B3GALNT2 adds a single GalNAc residue within the alpha-dystroglycan O-mannosyl glycan; the high-level "glycoprotein biosynthetic process" adds little specificity over the more informative O-mannosylation term. Replace with the specific O-mannosylation process term (consistent with the IMP annotation to the same term).
Proposed replacements:
protein O-linked glycosylation via mannose
|
|
GO:0016020
membrane
|
IEA
GO_REF:0000002 |
MARK AS OVER ANNOTATED |
Summary: Trivial location from the InterPro transmembrane signature. The protein is a type II single-pass membrane protein, so "membrane" is correct but uninformative; the specific ER/Golgi membrane terms supersede it.
|
|
GO:0016758
hexosyltransferase activity
|
IEA
GO_REF:0000002 |
MODIFY |
Summary: Broad InterPro-derived MF term (grandparent of the specific activity). The enzyme transfers a hexosamine (GalNAc), so the more precise acetylgalactosaminyltransferase activity (GO:0008376) is the appropriate term and is experimentally supported.
Proposed replacements:
acetylgalactosaminyltransferase activity
|
|
GO:0005515
protein binding
|
IPI
PMID:32296183 A reference map of the human binary protein interactome. |
MARK AS OVER ANNOTATED |
Summary: Generic "protein binding" from a high-throughput binary interactome (Y2H) screen reporting an interaction with TMBIM1. Per curation guidelines this term is uninformative about molecular function, and there is no evidence the TMBIM1 interaction is functionally relevant to the alpha-dystroglycan glycosylation pathway. Over-annotation; not a core function.
|
|
GO:0006493
protein O-linked glycosylation
|
TAS
Reactome:R-HSA-8932505 |
MODIFY |
Summary: Reactome traceable annotation (DAG1 core M3 glycosylations). Correct directionally; same generality issue as the IBA O-glycosylation term. The Reactome pathway is specifically about alpha-DG core M3 O-mannosyl glycan synthesis, so the more specific O-mannosylation term is preferable.
Proposed replacements:
protein O-linked glycosylation via mannose
|
|
GO:0008376
acetylgalactosaminyltransferase activity
|
TAS
Reactome:R-HSA-8931648 |
ACCEPT |
Summary: Correct and specific molecular function from the Reactome reaction "B3GALNT2 transfers GalNAc to GlcNAc-Man-DAG1". This is the core catalytic activity of the enzyme. Accept (concordant with the IDA annotation).
|
|
GO:0005789
endoplasmic reticulum membrane
|
TAS
Reactome:R-HSA-8931648 |
ACCEPT |
Summary: Reactome places the reaction at the ER membrane, consistent with the experimental ER localization (PMID:23453667) and the fact that the enzyme is a single-pass ER/Golgi membrane protein acting on the O-mannosyl glycan that is assembled in the ER. Accept; this is the precise membrane sub-location.
|
|
GO:0008376
acetylgalactosaminyltransferase activity
|
IDA
PMID:23929950 SGK196 is a glycosylation-specific O-mannose kinase required... |
ACCEPT |
Summary: Direct experimental demonstration: recombinant B3GALNT2 transfers GalNAc from UDP-GalNAc onto the GlcNAc-beta4-Man-O-peptide produced by POMGNT2, forming GalNAc-beta3-GlcNAc-beta4-Man. This is the best-supported molecular function and the core catalytic activity. Accept.
|
|
GO:0006493
protein O-linked glycosylation
|
IDA
PMID:23929950 SGK196 is a glycosylation-specific O-mannose kinase required... |
MODIFY |
Summary: Experimentally supported involvement in O-linked glycosylation via direct assay on the alpha-DG O-mannosyl glycan. As elsewhere, the more specific child term "protein O-linked glycosylation via mannose" (GO:0035269) more precisely reflects the demonstrated O-mannosyl (core M3) elongation.
Proposed replacements:
protein O-linked glycosylation via mannose
|
|
GO:0005783
endoplasmic reticulum
|
IDA
PMID:23453667 Mutations in B3GALNT2 cause congenital muscular dystrophy an... |
ACCEPT |
Summary: Direct experimental localization: B3GALNT2 localized to the ER, and disease missense variants (e.g. G247E, V268M) perturbed this localization. This is the core, experimentally supported subcellular location for the alpha-DG function. Accept.
|
|
GO:0009101
glycoprotein biosynthetic process
|
IMP
PMID:23453667 Mutations in B3GALNT2 cause congenital muscular dystrophy an... |
MODIFY |
Summary: Mutant-phenotype evidence (patient/zebrafish loss of function causes alpha-DG hypoglycosylation) does support a role in glycoprotein biosynthesis, so this is not incorrect. However the term is very general for a single-sugar transferase; the specific process is O-mannosyl (core M3) glycan elongation of alpha-dystroglycan. Replace with the specific O-mannosylation process term.
Proposed replacements:
protein O-linked glycosylation via mannose
|
Q: Besides alpha-dystroglycan, are there other physiological protein substrates that carry the GalNAc-beta3-GlcNAc-beta4-Man (core M3) structure built by B3GALNT2 in vivo?
Q: Is B3GALNT2 active in the ER, the Golgi, or both for the alpha-DG pathway, and does its compartmentalization differ from canonical Golgi GT31 family members?
Q: Does the in vitro activity toward N-glycan and core-2 O-GalNAc acceptors (reported in the original characterization) reflect any biological function, or is the O-mannosyl core M3 its sole in vivo role? Glycoproteomics (PMID:30898876) shows B3GALNT2-dependent type-I LacdiNAc on N-glycans of intracellular/ER glycoproteins (e.g. LRP1, nicastrin), but the physiological significance of these N-glycan modifications is not yet established.
Experiment: Glycoproteomic / mass-spectrometric profiling of alpha-dystroglycan and the broader glycoproteome in B3GALNT2-knockout versus wild-type cells to confirm loss of the GalNAc-beta3-GlcNAc-beta4-Man core M3 structure and to identify any additional core-M3-bearing substrates.
Experiment: In vitro reconstitution of the POMGNT2 -> B3GALNT2 -> POMK reaction sequence with defined glycopeptide acceptors to quantify B3GALNT2 kinetics on the physiological O-mannosyl acceptor and confirm strict dependence of POMK phosphorylation on prior B3GALNT2 action.
Experiment: Structure-function analysis of MDDGA11 missense variants (e.g. G247E, V268M, R292P) measuring catalytic activity, ER retention/localization, and protein stability to dissect how each impairs alpha-DG glycosylation.
=== UNIPROT METADATA ===
UniProt ID: Q8NCR0
Entry Name: B3GL2_HUMAN
Gene Name: B3GALNT2
Protein Name: UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2
EC Number: 2.4.1.313
Organism: Homo sapiens (Human)
NCBI Taxonomy ID: 9606
Function: Beta-1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc-beta-1-3GlcNAc, on N- and O- glycans. Has no galactose nor galactosaminyl transferase activity toward any acceptor substrate. Involved in alpha-dystroglycan (DAG1) glycosylation: acts coordinately with GTDC2/POMGnT2 to synthesize a GalNAc-beta3-GlcNAc-beta-terminus at the 4-position of protein O- mannose in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4- (phosphate-6-)mannose), a carbohydrate structure present in alpha- dystroglycan, which is required for binding laminin G-like domain- containing extracellular proteins with high affinity.
Subcellular Location: Golgi apparatus membrane
======================
Prepare a comprehensive literature-backed research report for GO annotation review of the target gene.
Focus on:
Structure the report as:
Use citations for all substantive claims.
Gene: B3GALNT2
Organism: Homo sapiens
UniProt ID: Q8NCR0
EC Number: 2.4.1.313
B3GALNT2 encodes UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2, a glycosyltransferase that catalyzes the synthesis of a unique carbohydrate structure, GalNAc-beta-1,3-GlcNAc (type-I LacdiNAc), on glycoproteins (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 1-2). The enzyme's primary and best-characterized function is in the O-mannosylation pathway of alpha-dystroglycan (α-DG), where it synthesizes the core M3 glycan trisaccharide essential for functional glycosylation and laminin binding (stevens2013mutationsinb3galnt2 pages 1-2, sheikh2017recentadvancementsin pages 1-5, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2). B3GALNT2 localizes to the endoplasmic reticulum (ER) and acts coordinately with GTDC2/POMGNT2 in a sequential enzymatic pathway (stevens2013mutationsinb3galnt2 pages 1-2, sheikh2017recentadvancementsin pages 1-5, sheikh2017recentadvancementsin pages 5-9). Mutations in B3GALNT2 cause dystroglycanopathies, a spectrum of congenital muscular dystrophies with variable brain involvement ranging from severe Walker-Warburg syndrome to milder forms (stevens2013mutationsinb3galnt2 pages 1-2, sharafeldin2025malformationsofcore pages 1-3, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2). The gene's core function centers on glycosylation chemistry and pathway biology; roles in apoptosis, inflammation, or signaling complexes are not directly supported by current evidence and should be considered context-specific or over-extended annotations.
B3GALNT2 functions as a beta-1,3-N-acetylgalactosaminyltransferase (EC 2.4.1.313) that transfers N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the 3-position hydroxyl group of N-acetylglucosamine (GlcNAc) residues, forming the type-I LacdiNAc disaccharide (GalNAcβ1-3GlcNAc) (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 1-2, sheikh2017recentadvancementsin pages 1-5). Importantly, B3GALNT2 has no galactose transferase activity nor broad galactosaminyl transferase activity toward other acceptor substrates (stevens2013mutationsinb3galnt2 pages 1-2).
| Enzymatic Activity | EC Number | Donor Substrate | Acceptor Substrate | Product Structure | Key References |
|---|---|---|---|---|---|
| UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase activity; transfers N-acetylgalactosamine (GalNAc) in a β1,3 linkage to terminal GlcNAc to generate type-I LacdiNAc | EC 2.4.1.313 | UDP-GalNAc | GlcNAc-containing acceptors; biochemically defined as transfer to the hydroxyl at position 3 of GlcNAc | GalNAcβ1-3GlcNAc (type-I LacdiNAc, LDN) | (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 1-2) |
| Core M3 biosynthetic step in α-dystroglycan O-mannosylation; acts after POMGNT2/GTDC2 adds β1,4-GlcNAc to O-Man and before POMK-dependent phosphorylation | EC 2.4.1.313 | UDP-GalNAc | GlcNAcβ1-4Man-O-Ser/Thr on α-dystroglycan (core M3 precursor) | GalNAcβ1-3GlcNAcβ1-4Man-O-Ser/Thr (core M3 trisaccharide) | (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, bigotti2021highdegreeof pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2) |
| Required for formation of the laminin-binding glycan pathway on α-dystroglycan; loss of activity causes hypoglycosylation of α-dystroglycan and impaired laminin binding | EC 2.4.1.313 | UDP-GalNAc | α-Dystroglycan core M3 acceptor in the O-mannosylation pathway | Core M3-derived phospho-trisaccharide precursor for downstream matriglycan elaboration | (stevens2013mutationsinb3galnt2 pages 1-2, sheikh2017recentadvancementsin pages 1-5, willer2014theglucuronyltransferaseb4gat1 pages 1-2) |
| Also synthesizes type-I LacdiNAc on N-glycans of mammalian glycoproteins, with evidence for intracellular glycoprotein carriers | EC 2.4.1.313 | UDP-GalNAc | N-glycan terminal GlcNAc residues on selected intracellular glycoproteins | GalNAcβ1-3GlcNAc on N-glycans | (nakane2019identificationofmammalian pages 1-2, nakane2019identificationofmammalian pages 2-3) |
| Substrate specificity is narrow: B3GALNT2 is characterized as a β1,3-N-acetylgalactosaminyltransferase that forms type-I LDN, rather than a galactosyltransferase or a broad-spectrum GalNAc transferase | EC 2.4.1.313 | UDP-GalNAc | Specific GlcNAc-bearing acceptors, especially the core M3 pathway intermediate | Type-I LacdiNAc-containing structures; not galactose-containing products | (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 1-2, sheikh2017recentadvancementsin pages 1-5) |
Table: This table summarizes the core enzymatic function, substrate specificity, and glycan products of human B3GALNT2. It is useful for GO review because it separates the enzyme’s direct catalytic activity from its broader pathway role in α-dystroglycan glycosylation.
The enzyme exhibits strict substrate specificity. Biochemical studies have demonstrated that B3GALNT2 specifically recognizes GlcNAc-containing acceptors and catalyzes the formation of β1,3-glycosidic linkages rather than β1,4-linkages, distinguishing it from type-II LacdiNAc synthases B4GALNT3 and B4GALNT4 (nakane2019identificationofmammalian pages 1-2, nakane2019identificationofmammalian pages 2-3, praissman2014mammalianomannosylationpathway pages 2-4). In vitro characterization confirmed that B3GALNT2 transfers GalNAc in a β1,3-linkage to terminal GlcNAc residues on both O-mannosyl glycans and N-glycans (nakane2019identificationofmammalian pages 1-2, sheikh2017recentadvancementsin pages 1-5).
The most physiologically significant substrate for B3GALNT2 is the core M3 precursor of α-dystroglycan O-mannosyl glycans. In this pathway, B3GALNT2 acts after POMGNT2 (also known as GTDC2) adds β1,4-GlcNAc to O-mannose, generating the acceptor substrate GlcNAcβ1-4Man-O-Ser/Thr (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, bigotti2021highdegreeof pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2). B3GALNT2 then adds GalNAc in a β1,3-linkage to this GlcNAc, producing the core M3 trisaccharide GalNAcβ1-3GlcNAcβ1-4Man-O-Ser/Thr (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3). This trisaccharide is subsequently phosphorylated at the mannose 6-position by POMK, creating the phospho-trisaccharide that serves as the acceptor for downstream ribitol-phosphate and matriglycan elaboration by FKTN, FKRP, and LARGE enzymes (sheikh2017recentadvancementsin pages 1-5, willer2014theglucuronyltransferaseb4gat1 pages 1-2, sheikh2017recentadvancementsin pages 5-9).
Recent structural and pathway studies (2014-2025) have established this sequential biosynthetic order: POMT1/POMT2 → POMGNT2 → B3GALNT2 → POMK → B4GAT1 → FKTN/FKRP → LARGE1/2, culminating in the laminin-binding matriglycan glycan (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3, bigotti2021highdegreeof pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2).
Beyond α-dystroglycan, B3GALNT2 also synthesizes type-I LacdiNAc on N-glycans of other mammalian glycoproteins. Proteomic studies using isotope-coded glycosylation site-specific tagging (IGOT) and mass spectrometry identified more than 150 glycoproteins carrying B3GALNT2-generated type-I LacdiNAc structures (nakane2019identificationofmammalian pages 1-2, nakane2019identificationofmammalian pages 2-3). Most of these carrier glycoproteins localize to intracellular organelles, particularly the endoplasmic reticulum, distinguishing them from the extracellular glycoproteins that carry type-II LacdiNAc synthesized by B4GALNT3 and B4GALNT4 (nakane2019identificationofmammalian pages 1-2, nakane2019identificationofmammalian pages 2-3). The physiological significance of these additional substrates remains to be fully elucidated.
The primary biological process for B3GALNT2 is the O-mannosylation of α-dystroglycan (stevens2013mutationsinb3galnt2 pages 1-2, sheikh2017recentadvancementsin pages 1-5, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2). α-Dystroglycan is a heavily glycosylated peripheral membrane protein that binds laminin and other extracellular matrix proteins containing laminin-G domains (bigotti2021highdegreeof pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3). This binding is absolutely dependent on proper O-mannosyl glycosylation, specifically the matriglycan heteropolysaccharide structure built on the core M3 scaffold (sheikh2017recentadvancementsin pages 1-5, bigotti2021highdegreeof pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2).
Loss of B3GALNT2 function results in hypoglycosylation of α-dystroglycan, as demonstrated by reduced reactivity with the glycan-specific antibody IIH6 and impaired laminin binding in patient-derived fibroblasts and muscle tissue (stevens2013mutationsinb3galnt2 pages 1-2, stevens2013mutationsinb3galnt2 pages 2-3). Zebrafish knockdown studies confirmed that b3galnt2 deficiency reduces functional dystroglycan glycosylation and recapitulates key features of human dystroglycanopathy (stevens2013mutationsinb3galnt2 pages 1-2).
| Biological Process | Supporting Evidence | Clinical Phenotype | Core vs Context-Specific |
|---|---|---|---|
| α-dystroglycan O-mannosylation and functional glycosylation | B3GALNT2 adds GalNAc in β1,3 linkage to the POMGNT2-generated GlcNAcβ1,4Man core M3 precursor on α-dystroglycan, producing the trisaccharide required for downstream phosphorylation and matriglycan-dependent functional glycosylation; loss of B3GALNT2 reduces functional α-DG glycosylation in patient cells and zebrafish (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, stevens2013mutationsinb3galnt2 pages 1-2) | Congenital muscular dystrophy / dystroglycanopathy with hypoglycosylated α-DG (stevens2013mutationsinb3galnt2 pages 1-2) | Core / primary |
| Muscle integrity and sarcolemma stability | Proper α-DG glycosylation is required for the dystrophin-glycoprotein complex to link cytoskeleton to extracellular matrix; defective B3GALNT2 disrupts this pathway, causing reduced laminin-binding glycan and muscle pathology, with zebrafish knockdown showing disordered muscle fibers and sarcolemmal/myoseptal damage (stevens2013mutationsinb3galnt2 pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3) | Congenital muscular dystrophy, hypotonia, impaired motor development, muscle fiber damage (stevens2013mutationsinb3galnt2 pages 1-2) | Core downstream consequence of primary glycosylation defect |
| Brain development and neuronal migration | Dystroglycan glycosylation is important for brain development; B3GALNT2 mutations are associated with structural brain involvement, and dystroglycanopathies are linked to abnormal neuronal migration/cobblestone-type cortical malformations (stevens2013mutationsinb3galnt2 pages 1-2, sharafeldin2025malformationsofcore pages 1-3, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2) | Polymicrogyria/cortical dysplasia, cerebellar cysts, thin corpus callosum, abnormal white matter, developmental delay, severe neurodevelopmental involvement (stevens2013mutationsinb3galnt2 pages 1-2) | Core organism-level biological role in affected tissues, downstream of enzymatic function |
| Extracellular matrix organization via dystroglycan-laminin binding | Core M3-derived glycosylation on α-DG is essential for laminin-G domain binding; B3GALNT2-dependent synthesis contributes to the ligand-binding glycan scaffold that organizes basement membrane interactions between cells and ECM (sheikh2017recentadvancementsin pages 1-5, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3) | Reduced laminin binding, basement membrane interaction defects, neuromuscular and brain malformations (stevens2013mutationsinb3galnt2 pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2) | Core / primary pathway consequence |
| Apoptosis, inflammation, pyroptosis, synaptic remodeling, signaling-complex roles | Available evidence in the retrieved literature does not support direct assignment of B3GALNT2 as an apoptosis, inflammatory signaling, pyroptosis, or synaptic remodeling effector. Any such phenomena are better interpreted as secondary consequences of broader glycosylation or tissue pathology rather than direct core B3GALNT2 function (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3) | No specific B3GALNT2-linked primary apoptosis or inflammatory phenotype established in the cited evidence | Context-specific / insufficient direct evidence |
| Type-I LacdiNAc synthesis on intracellular glycoproteins outside α-DG pathway | B3GALNT2 also synthesizes type-I LacdiNAc on selected N-glycans of intracellular glycoproteins, especially ER/intracellular proteins, indicating a broader biochemical capability beyond α-DG modification (nakane2019identificationofmammalian pages 1-2, nakane2019identificationofmammalian pages 2-3) | No clearly established human disease phenotype from this activity independent of dystroglycanopathy in the cited evidence | Context-specific biochemical activity; not yet the best-supported GO biological-process focus |
Table: This table summarizes the best-supported biological processes involving B3GALNT2 and distinguishes core functions from secondary or insufficiently supported roles. It is useful for GO review because it separates direct glycosylation biology from broader disease consequences and over-extended annotations.
Through its role in α-dystroglycan glycosylation, B3GALNT2 is essential for muscle structural integrity and development (stevens2013mutationsinb3galnt2 pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3). α-Dystroglycan is a key component of the dystrophin-glycoprotein complex (DGC), which links the intracellular cytoskeleton to the extracellular matrix, providing mechanical stability to the sarcolemma during muscle contraction (endo2015glycobiologyofαdystroglycan pages 2-3, sheikh2017recentadvancementsin pages 5-9).
Patients with B3GALNT2 mutations present with congenital muscular dystrophy characterized by hypotonia, delayed motor milestones, and progressive muscle weakness (stevens2013mutationsinb3galnt2 pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2). Zebrafish b3galnt2 morphants show disordered muscle fibers with evidence of damage to both the myosepta and sarcolemma, recapitulating the human muscular phenotype (stevens2013mutationsinb3galnt2 pages 1-2).
B3GALNT2 plays a critical role in brain development, particularly in neuronal migration. Mutations in B3GALNT2 are associated with structural brain malformations classified as cobblestone lissencephaly (type II lissencephaly), a neuronal migration disorder characterized by disrupted cortical layering (stevens2013mutationsinb3galnt2 pages 1-2, sharafeldin2025malformationsofcore pages 1-3, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2). Clinical features include polymicrogyria (excessive small gyri), cerebellar cysts, thin or absent corpus callosum, and diffusely abnormal white matter on brain MRI (stevens2013mutationsinb3galnt2 pages 1-2).
The mechanism underlying these brain malformations involves defective dystroglycan-mediated interactions between migrating neurons and the basement membrane/extracellular matrix during cortical development (sharafeldin2025malformationsofcore pages 1-3, bigotti2021highdegreeof pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2). Recent reviews (2021-2025) position B3GALNT2-related dystroglycanopathies within the broader category of congenital disorders of glycosylation (CDG) that affect brain development through O-mannosylation pathway defects (sharafeldin2025malformationsofcore pages 1-3, togayachi2026glycanrelatedgenesand pages 1-2).
B3GALNT2 contributes to extracellular matrix organization indirectly through its role in synthesizing the laminin-binding glycan on α-dystroglycan (sheikh2017recentadvancementsin pages 1-5, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2). The core M3-derived glycosylation is essential for α-dystroglycan to bind laminin-211, perlecan, agrin, and other basement membrane proteins, thereby organizing cell-ECM interactions in muscle, brain, and other tissues (bigotti2021highdegreeof pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3).
The current literature does not support direct roles for B3GALNT2 in apoptosis, inflammatory signaling, pyroptosis, or synaptic remodeling as primary functions (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3). These processes may occur secondarily to tissue pathology in dystroglycanopathies but should not be annotated as core B3GALNT2 functions without direct mechanistic evidence. Similarly, while some glycosylation-related genes have been implicated in inflammatory contexts, no B3GALNT2-specific evidence supports such annotations in the reviewed literature.
B3GALNT2 localizes to the endoplasmic reticulum (ER), not primarily to the Golgi apparatus (stevens2013mutationsinb3galnt2 pages 1-2, stevens2013mutationsinb3galnt2 pages 2-3). Patient-derived cell studies and transfection experiments demonstrated that B3GALNT2 exhibits ER localization, and certain missense mutations perturb this localization (stevens2013mutationsinb3galnt2 pages 1-2, stevens2013mutationsinb3galnt2 pages 2-3). Brefeldin A experiments, which inhibit ER-to-Golgi transport, showed that B3GALNT2-dependent type-I LacdiNAc synthesis occurs in the ER, contrasting with Golgi-resident glycosyltransferases like B4GALNT3/4 (nakane2019identificationofmammalian pages 2-3).
While UniProt metadata lists "Golgi apparatus membrane" as the subcellular location, primary experimental evidence more strongly supports ER localization for active B3GALNT2 (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 2-3, sheikh2017recentadvancementsin pages 5-9). The O-mannosylation pathway spans both ER and Golgi compartments, with early steps (POMT1/2, POMGNT2, B3GALNT2, POMK) occurring in the ER and later elaboration steps (B4GAT1, FKTN/FKRP, LARGE) occurring in the Golgi (sheikh2017recentadvancementsin pages 1-5, sharafeldin2025malformationsofcore pages 1-3, willer2014theglucuronyltransferaseb4gat1 pages 1-2).
| Localization/Complex | Evidence | Sequential Pathway Position | Comments |
|---|---|---|---|
| Endoplasmic reticulum (ER) localization of B3GALNT2 | Patient and cell-based studies reported that B3GALNT2 localized to the ER, and some missense variants perturbed this localization (stevens2013mutationsinb3galnt2 pages 1-2, stevens2013mutationsinb3galnt2 pages 2-3) | Acts in early secretory pathway during α-dystroglycan O-mannosyl glycan assembly | This is the strongest direct localization evidence retrieved for human B3GALNT2; it argues against assigning the active enzyme primarily to cytosol, nucleus, or plasma-membrane signaling complexes (stevens2013mutationsinb3galnt2 pages 1-2) |
| Relationship to Golgi | B3GALNT2-dependent type-I LacdiNAc synthesis was observed under conditions showing ER localization, whereas Golgi-resident glycosyltransferases such as B4GALNT3/4 act later or in different compartments; brefeldin A experiments supported ER-associated B3GALNT2 activity, while other α-DG-modifying enzymes are Golgi-localized (nakane2019identificationofmammalian pages 2-3, willer2014theglucuronyltransferaseb4gat1 pages 1-2) | Upstream of clearly Golgi-resident post-phosphorylation steps | Evidence supports an ER/early secretory localization for B3GALNT2 rather than a canonical medial/trans-Golgi assignment, although the overall α-DG pathway spans both ER and Golgi compartments (sheikh2017recentadvancementsin pages 1-5, sharafeldin2025malformationsofcore pages 1-3) |
| Functional coordination with GTDC2/POMGNT2 | Reviews of core M3 biosynthesis place POMGNT2/GTDC2 as the enzyme that adds β1,4-GlcNAc to O-mannose, after which B3GALNT2 adds β1,3-GalNAc to generate the core M3 trisaccharide (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, bigotti2021highdegreeof pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2) | Immediately after POMGNT2/GTDC2 | The evidence supports sequential pathway coupling, not necessarily a stable physical complex. For GO review, “acts coordinately with” is safer than asserting direct obligate complex formation (sheikh2017recentadvancementsin pages 1-5, bigotti2021highdegreeof pages 1-2) |
| Position relative to POMT1/POMT2, POMGNT2, and POMK | O-mannosylation begins with POMT1/POMT2 adding O-Man; POMGNT2 then adds β1,4-GlcNAc; B3GALNT2 adds β1,3-GalNAc; POMK subsequently phosphorylates the mannose 6-position of the assembled trisaccharide (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2) | After POMT1/POMT2 and POMGNT2; before POMK | This is the best-supported pathway placement for B3GALNT2 and should be treated as core annotation-relevant biology (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2) |
| Downstream pathway partners: B4GAT1, FKTN, FKRP, LARGE1/2 | After the B3GALNT2/POMK-dependent core M3 phospho-trisaccharide is formed, downstream enzymes including B4GAT1, FKTN, FKRP, and LARGE1/2 elaborate the linker and matriglycan needed for ligand binding (willer2014theglucuronyltransferaseb4gat1 pages 1-2, sheikh2017recentadvancementsin pages 5-9, bigotti2021highdegreeof pages 1-2) | Downstream of B3GALNT2 | These enzymes belong to the same functional pathway but are not evidence that B3GALNT2 itself is part of a stable multimeric complex with each one; pathway membership is stronger than physical-complex annotation here (willer2014theglucuronyltransferaseb4gat1 pages 1-2, sheikh2017recentadvancementsin pages 5-9) |
| Broader intracellular glycoprotein context | Proteomics in transfected cells showed B3GALNT2 can synthesize type-I LacdiNAc on N-glycans of mainly intracellular glycoproteins, many associated with ER/intracellular organelles (nakane2019identificationofmammalian pages 1-2, nakane2019identificationofmammalian pages 2-3) | Parallel biochemical capability outside the α-DG core M3 pathway | This broadens biochemical scope but currently has less direct GO-process support than α-dystroglycan glycosylation; it may be better treated as context-specific or secondary until more in vivo functional evidence is available (nakane2019identificationofmammalian pages 1-2) |
| Activation, maturation, or proteolytic processing of B3GALNT2 | No retrieved evidence indicates that B3GALNT2 itself requires proteolytic activation, autocatalytic maturation, or regulated cleavage to become active (stevens2013mutationsinb3galnt2 pages 1-2, sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2) | Not applicable / no demonstrated dedicated activation step | Distinguish this from DAG1/α-dystroglycan, whose precursor undergoes processing and whose glycosylation is the pathway output; proteolytic processing is relevant to substrate biology, not established as a maturation mechanism for B3GALNT2 itself (endo2015glycobiologyofαdystroglycan pages 2-3, sheikh2017recentadvancementsin pages 5-9) |
Table: This table summarizes the strongest evidence for B3GALNT2 subcellular localization and its place in the α-dystroglycan O-mannosylation pathway. It is useful for GO review because it separates direct localization and pathway-order evidence from weaker claims about stable complexes or activation mechanisms.
B3GALNT2 functions coordinately with GTDC2/POMGNT2 in the sequential assembly of the core M3 glycan (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, bigotti2021highdegreeof pages 1-2, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2). However, current evidence supports pathway coupling rather than a stable obligate physical complex. The term "acts coordinately with" is more appropriate than asserting direct complex formation in the absence of co-immunoprecipitation or structural data (sheikh2017recentadvancementsin pages 1-5, bigotti2021highdegreeof pages 1-2).
B3GALNT2 is part of the broader O-mannosylation pathway involving multiple enzymes: POMT1, POMT2, POMGNT2, B3GALNT2, POMK, B4GAT1, FKTN, FKRP, and LARGE1/2 (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3, bigotti2021highdegreeof pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2). These enzymes share a common functional pathway but are not necessarily components of a stable multi-enzyme complex. GO curators should annotate pathway membership rather than over-interpreting as physical complex formation.
No evidence indicates that B3GALNT2 itself requires proteolytic activation, autocatalytic maturation, or regulated cleavage to become enzymatically active (stevens2013mutationsinb3galnt2 pages 1-2, sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2). This distinguishes B3GALNT2 from its substrate DAG1/α-dystroglycan, which undergoes post-translational cleavage into α- and β-subunits (endo2015glycobiologyofαdystroglycan pages 2-3, sheikh2017recentadvancementsin pages 5-9). Proteolytic processing is relevant to substrate biology, not to B3GALNT2 enzyme maturation.
Core enzymatic function: B3GALNT2 should be annotated with UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase activity (EC 2.4.1.313) and type-I LacdiNAc synthesis (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 1-2, sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2). This is the most direct and conserved molecular function with strong biochemical support.
α-Dystroglycan glycosylation: Annotation to protein O-mannose glycan biosynthetic process, specifically the core M3 branch of α-dystroglycan O-mannosylation, is well supported (stevens2013mutationsinb3galnt2 pages 1-2, sheikh2017recentadvancementsin pages 1-5, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2).
Muscle and brain development: These organism-level processes are strongly supported as downstream consequences of defective α-DG glycosylation (stevens2013mutationsinb3galnt2 pages 1-2, sharafeldin2025malformationsofcore pages 1-3, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3). However, B3GALNT2 acts indirectly through glycan assembly rather than as a developmental transcription factor or signaling molecule. Annotations should clearly frame participation as occurring through α-dystroglycan glycosylation or ECM linkage mechanisms.
Extracellular matrix organization: Supported as an indirect role via α-dystroglycan laminin-binding function (sheikh2017recentadvancementsin pages 1-5, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3).
Cytosol/nucleus localization: No evidence supports cytosolic or nuclear residency; primary data support ER localization (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 2-3, sheikh2017recentadvancementsin pages 5-9). Do not annotate to cytosol, cytoplasm, or nucleus.
Apoptosis and inflammatory signaling: Not established as direct B3GALNT2 functions; any such phenotypes are secondary to glycosylation defects or tissue pathology (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3). Avoid these annotations.
Pyroptosis: No evidence links B3GALNT2 to inflammasome biology or pyroptotic cell death (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3). Exclude this annotation.
Synaptic remodeling/synapse organization: Dystroglycan defects affect nervous system structure, but B3GALNT2 itself does not directly remodel synapses (sharafeldin2025malformationsofcore pages 1-3, bigotti2021highdegreeof pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3). This would be an overextension from substrate biology.
Signaling complexes: B3GALNT2 is a secretory pathway glycosyltransferase, not a demonstrated component of cell-surface or cytosolic signaling complexes (willer2014theglucuronyltransferaseb4gat1 pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3, sheikh2017recentadvancementsin pages 5-9). Avoid annotating to dystrophin-associated complexes, receptor complexes, or signaling complexes unless direct physical-complex evidence emerges.
| Annotation Type | Risk Level (High/Medium/Low) | Rationale | Recommendation |
|---|---|---|---|
| Core enzymatic function: UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase activity / type-I LacdiNAc synthesis | Low | Strong biochemical and pathway evidence supports B3GALNT2 as a β1,3-N-acetylgalactosaminyltransferase that adds GalNAc to GlcNAc to form GalNAcβ1-3GlcNAc, including on the core M3 precursor of α-dystroglycan; this is the most direct and conserved molecular function assignment (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 1-2, sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2) | Keep/priority GO MF annotation. Prefer specific transferase terms tied to GalNAc transfer to GlcNAc-containing acceptors; avoid broader or incorrect galactosyltransferase assignments. |
| α-dystroglycan glycosylation / protein O-mannose glycan biosynthetic process (core M3 branch) | Low | Multiple studies place B3GALNT2 directly in the α-dystroglycan core M3 pathway, acting after POMGNT2 and before POMK; pathogenic variants reduce functional α-DG glycosylation and laminin binding (stevens2013mutationsinb3galnt2 pages 1-2, sheikh2017recentadvancementsin pages 1-5, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, willer2014theglucuronyltransferaseb4gat1 pages 1-2) | Keep as a core BP annotation. Use wording that reflects direct participation in α-dystroglycan O-mannosyl glycan biosynthesis rather than vague “muscular dystrophy pathway” terms. |
| Muscle development / brain development / neuronal migration / extracellular matrix organization | Medium | These are strongly supported organism-level consequences of defective α-DG glycosylation, especially for muscle integrity and cortical/brain malformations, but B3GALNT2 acts indirectly through glycan assembly rather than as a developmental regulator per se (stevens2013mutationsinb3galnt2 pages 1-2, sharafeldin2025malformationsofcore pages 1-3, bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3) | Curate cautiously. Accept downstream process annotations only when framed as participation through α-dystroglycan glycosylation or ECM linkage; avoid over-specific claims unless backed by direct experimental evidence in human or a justified ortholog model. |
| Cytosol localization / cytoplasm / nucleus localization | High | The strongest direct localization evidence supports B3GALNT2 in the endoplasmic reticulum/early secretory pathway; no retrieved evidence supports cytosolic or nuclear residency as an active functional site (stevens2013mutationsinb3galnt2 pages 1-2, nakane2019identificationofmammalian pages 2-3, sheikh2017recentadvancementsin pages 5-9) | Do not annotate to cytosol, cytoplasm, or nucleus without new direct localization data. Prefer ER/secretory pathway localization; avoid inferring from broad proteomic or disease literature. |
| Apoptosis / inflammatory signaling | High | Retrieved literature does not establish B3GALNT2 as a direct regulator of apoptosis or inflammatory signaling. Any such phenotypes are more plausibly secondary to glycosylation defects, tissue pathology, or extrapolation from other glycogenes (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3) | Avoid direct GO BP annotations for apoptosis or inflammatory signaling. Only consider if future mechanistic studies show a direct B3GALNT2-dependent role beyond general dystroglycanopathy pathology. |
| Pyroptosis | High | No direct evidence in the retrieved B3GALNT2 literature links the gene product to inflammasome biology or pyroptotic cell death (sheikh2017recentadvancementsin pages 1-5, praissman2014mammalianomannosylationpathway pages 1-2, sharafeldin2025malformationsofcore pages 1-3) | Exclude pyroptosis annotations. Treat any proposed link as unsupported unless a dedicated mechanistic study demonstrates direct involvement. |
| Synaptic remodeling / synapse organization | High | Dystroglycan pathway defects can affect nervous system structure and neuromuscular synapses, but the retrieved evidence does not show B3GALNT2 itself directly remodeling synapses; this would be an overextension from substrate biology and disease phenotype (sharafeldin2025malformationsofcore pages 1-3, bigotti2021highdegreeof pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3) | Do not assign synaptic remodeling/synapse organization unless direct experimental evidence shows B3GALNT2-dependent synaptic mechanism in vivo. If needed, prefer broader developmental annotations with clear caveats. |
| Over-extended signaling complex assignments / plasma membrane signaling complexes | High | B3GALNT2 is a glycosyltransferase of the secretory pathway, not a demonstrated component of cell-surface or cytosolic signaling complexes. Confusion may arise because its substrate α-DG participates in signaling and ECM linkage (willer2014theglucuronyltransferaseb4gat1 pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3, sheikh2017recentadvancementsin pages 5-9) | Avoid annotating B3GALNT2 as part of dystrophin-associated, receptor, or signaling complexes unless direct physical-complex evidence appears. Pathway association should not be converted into complex membership. |
Table: This table assesses which GO annotation categories for B3GALNT2 are well supported versus overextended. It helps curators prioritize core enzymatic and glycosylation annotations while avoiding unsupported localization and signaling claims.
Stevens et al. (2013) - First description of B3GALNT2 mutations causing congenital muscular dystrophy and hypoglycosylation of α-dystroglycan. Demonstrated reduced functional dystroglycan glycosylation in patient fibroblasts and muscle, ER localization of B3GALNT2, and zebrafish phenocopy of human disease (stevens2013mutationsinb3galnt2 pages 1-2).
DOI: 10.1016/j.ajhg.2013.01.016
URL: https://doi.org/10.1016/j.ajhg.2013.01.016
Praissman & Wells (2014) - Comprehensive review of mammalian O-mannosylation pathway, including detailed nomenclature for core M structures and placement of B3GALNT2 in the core M3 biosynthetic pathway (praissman2014mammalianomannosylationpathway pages 1-2).
DOI: 10.1021/bi500153y
URL: https://doi.org/10.1021/bi500153y
Willer et al. (2014) - Elucidated the role of B4GAT1 (downstream of B3GALNT2) as a glucuronyltransferase and demonstrated that FKRP, FKTN, TMEM5, and B4GAT1 localize to the Golgi for post-phosphorylation modification of α-DG (willer2014theglucuronyltransferaseb4gat1 pages 1-2).
DOI: 10.7554/eLife.03941
URL: https://doi.org/10.7554/eLife.03941
Nakane et al. (2019) - Identified mammalian glycoproteins carrying type-I LacdiNAc structures synthesized by B3GALNT2 using glycoproteomics. Showed that B3GALNT2 primarily transfers LDN to intracellular glycoproteins, delineating type-I from type-II LDN carriers (nakane2019identificationofmammalian pages 1-2).
DOI: 10.1074/jbc.ra118.006892
URL: https://doi.org/10.1074/jbc.ra118.006892
Sheikh et al. (2017) - Review of recent advancements in mammalian O-mannosylation, including substrate specificity and regulation of pathway enzymes (sheikh2017recentadvancementsin pages 1-5, sheikh2017recentadvancementsin pages 5-9).
DOI: 10.1093/glycob/cwx062
URL: https://doi.org/10.1093/glycob/cwx062
Endo (2015) - Review of glycobiology of α-dystroglycan and muscular dystrophy, describing O-mannosyl glycan structures and biosynthesis (endo2015glycobiologyofαdystroglycan pages 1-2, endo2015glycobiologyofαdystroglycan pages 2-3).
DOI: 10.1093/jb/mvu066
URL: https://doi.org/10.1093/jb/mvu066
Bouchet-Séraphin et al. (2015) - Review of dystroglycanopathies covering numerous genes involved in glycosylation of dystroglycan, including B3GALNT2 (bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2).
DOI: 10.3233/jnd-140047
URL: https://doi.org/10.3233/jnd-140047
Bigotti & Brancaccio (2021) - Phylogenetic and evolutionary analysis of enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan, including conservation of B3GALNT2 in Metazoa (bigotti2021highdegreeof pages 1-2).
DOI: 10.1098/rsob.210104
URL: https://doi.org/10.1098/rsob.210104
Sharaf-Eldin (2025) - Recent review on malformations of core M3 on α-dystroglycan as the leading cause of dystroglycanopathies, with updated pathway diagrams and disease mechanisms (sharafeldin2025malformationsofcore pages 1-3).
DOI: 10.1007/s12031-025-02320-z
URL: https://doi.org/10.1007/s12031-025-02320-z
Togayachi et al. (2026) - Comprehensive review of glycan-related genes and genetic disorders, including B3GALNT2 in the context of congenital disorders of glycosylation (togayachi2026glycanrelatedgenesand pages 1-2).
DOI: 10.1038/s10038-026-01463-0
URL: https://doi.org/10.1038/s10038-026-01463-0
B3GALNT2 is a well-characterized glycosyltransferase with a core molecular function of UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase activity (EC 2.4.1.313). Its primary biological role is in the O-mannosylation pathway of α-dystroglycan, where it synthesizes the core M3 trisaccharide essential for laminin-binding glycan maturation. The enzyme localizes to the endoplasmic reticulum and functions coordinately with POMGNT2 and other pathway enzymes in a sequential biosynthetic cascade. Mutations in B3GALNT2 cause dystroglycanopathies ranging from severe Walker-Warburg syndrome to milder congenital muscular dystrophy, with prominent brain malformations reflecting defective neuronal migration.
For GO annotation purposes, high-confidence annotations include the core transferase activity, α-dystroglycan glycosylation, and ER localization. Medium-risk annotations for muscle and brain development should be carefully framed as consequences of glycosylation defects. High-risk or unsupported annotations include cytosol/nucleus localization, apoptosis, inflammatory signaling, pyroptosis, synaptic remodeling, and membership in signaling complexes. These distinctions between core function and context-specific roles are critical for accurate GO curation.
References
(stevens2013mutationsinb3galnt2 pages 1-2): Elizabeth Stevens, Keren J. Carss, Sebahattin Cirak, A. Reghan Foley, Silvia Torelli, Tobias Willer, Dimira E. Tambunan, Shu Yau, Lina Brodd, Caroline A. Sewry, Lucy Feng, Goknur Haliloglu, Diclehan Orhan, William B. Dobyns, Gregory M. Enns, Melanie Manning, Amanda Krause, Mustafa A. Salih, Christopher A. Walsh, Matthew Hurles, Kevin P. Campbell, M. Chiara Manzini, Derek Stemple, Yung-Yao Lin, and Francesco Muntoni. Mutations in b3galnt2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan. American journal of human genetics, 92 3:354-65, Mar 2013. URL: https://doi.org/10.1016/j.ajhg.2013.01.016, doi:10.1016/j.ajhg.2013.01.016. This article has 225 citations and is from a highest quality peer-reviewed journal.
(nakane2019identificationofmammalian pages 1-2): Takahiro Nakane, Kiyohiko Angata, Takashi Sato, Hiroyuki Kaji, and Hisashi Narimatsu. Identification of mammalian glycoproteins with type-i lacdinac structures synthesized by the glycosyltransferase b3galnt2. Journal of Biological Chemistry, 294:7433-7444, May 2019. URL: https://doi.org/10.1074/jbc.ra118.006892, doi:10.1074/jbc.ra118.006892. This article has 17 citations and is from a domain leading peer-reviewed journal.
(sheikh2017recentadvancementsin pages 1-5): M Osman Sheikh, Stephanie M Halmo, and Lance Wells. Recent advancements in understanding mammalian o-mannosylation. Glycobiology, 27 9:806-819, Sep 2017. URL: https://doi.org/10.1093/glycob/cwx062, doi:10.1093/glycob/cwx062. This article has 127 citations and is from a peer-reviewed journal.
(bouchetseraphin2015dystroglycanopathiesaboutnumerous pages 1-2): Céline Bouchet-Séraphin, Sandrine Vuillaumier-Barrot, and Nathalie Seta. Dystroglycanopathies: about numerous genes involved in glycosylation of one single glycoprotein. Journal of Neuromuscular Diseases, 2:27-38, Feb 2015. URL: https://doi.org/10.3233/jnd-140047, doi:10.3233/jnd-140047. This article has 49 citations and is from a peer-reviewed journal.
(sheikh2017recentadvancementsin pages 5-9): M Osman Sheikh, Stephanie M Halmo, and Lance Wells. Recent advancements in understanding mammalian o-mannosylation. Glycobiology, 27 9:806-819, Sep 2017. URL: https://doi.org/10.1093/glycob/cwx062, doi:10.1093/glycob/cwx062. This article has 127 citations and is from a peer-reviewed journal.
(sharafeldin2025malformationsofcore pages 1-3): Wessam E. Sharaf-Eldin. Malformations of core m3 on α-dystroglycan are the leading cause of dystroglycanopathies. Journal of Molecular Neuroscience, Feb 2025. URL: https://doi.org/10.1007/s12031-025-02320-z, doi:10.1007/s12031-025-02320-z. This article has 2 citations and is from a peer-reviewed journal.
(praissman2014mammalianomannosylationpathway pages 1-2): Jeremy L. Praissman and Lance Wells. Mammalian o-mannosylation pathway: glycan structures, enzymes, and protein substrates. Biochemistry, 53:3066-3078, May 2014. URL: https://doi.org/10.1021/bi500153y, doi:10.1021/bi500153y. This article has 92 citations and is from a peer-reviewed journal.
(bigotti2021highdegreeof pages 1-2): Maria Giulia Bigotti and Andrea Brancaccio. High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan. Open Biology, Sep 2021. URL: https://doi.org/10.1098/rsob.210104, doi:10.1098/rsob.210104. This article has 12 citations and is from a peer-reviewed journal.
(willer2014theglucuronyltransferaseb4gat1 pages 1-2): Tobias Willer, Kei-ichiro Inamori, David Venzke, Corinne Harvey, Greg Morgensen, Yuji Hara, Daniel Beltrán Valero de Bernabé, Liping Yu, Kevin M Wright, and Kevin P Campbell. The glucuronyltransferase b4gat1 is required for initiation of large-mediated α-dystroglycan functional glycosylation. eLife, Oct 2014. URL: https://doi.org/10.7554/elife.03941, doi:10.7554/elife.03941. This article has 144 citations and is from a domain leading peer-reviewed journal.
(nakane2019identificationofmammalian pages 2-3): Takahiro Nakane, Kiyohiko Angata, Takashi Sato, Hiroyuki Kaji, and Hisashi Narimatsu. Identification of mammalian glycoproteins with type-i lacdinac structures synthesized by the glycosyltransferase b3galnt2. Journal of Biological Chemistry, 294:7433-7444, May 2019. URL: https://doi.org/10.1074/jbc.ra118.006892, doi:10.1074/jbc.ra118.006892. This article has 17 citations and is from a domain leading peer-reviewed journal.
(praissman2014mammalianomannosylationpathway pages 2-4): Jeremy L. Praissman and Lance Wells. Mammalian o-mannosylation pathway: glycan structures, enzymes, and protein substrates. Biochemistry, 53:3066-3078, May 2014. URL: https://doi.org/10.1021/bi500153y, doi:10.1021/bi500153y. This article has 92 citations and is from a peer-reviewed journal.
(endo2015glycobiologyofαdystroglycan pages 2-3): T. Endo. Glycobiology of α-dystroglycan and muscular dystrophy. Journal of biochemistry, 157 1:1-12, Nov 2015. URL: https://doi.org/10.1093/jb/mvu066, doi:10.1093/jb/mvu066. This article has 190 citations and is from a peer-reviewed journal.
(stevens2013mutationsinb3galnt2 pages 2-3): Elizabeth Stevens, Keren J. Carss, Sebahattin Cirak, A. Reghan Foley, Silvia Torelli, Tobias Willer, Dimira E. Tambunan, Shu Yau, Lina Brodd, Caroline A. Sewry, Lucy Feng, Goknur Haliloglu, Diclehan Orhan, William B. Dobyns, Gregory M. Enns, Melanie Manning, Amanda Krause, Mustafa A. Salih, Christopher A. Walsh, Matthew Hurles, Kevin P. Campbell, M. Chiara Manzini, Derek Stemple, Yung-Yao Lin, and Francesco Muntoni. Mutations in b3galnt2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan. American journal of human genetics, 92 3:354-65, Mar 2013. URL: https://doi.org/10.1016/j.ajhg.2013.01.016, doi:10.1016/j.ajhg.2013.01.016. This article has 225 citations and is from a highest quality peer-reviewed journal.
(togayachi2026glycanrelatedgenesand pages 1-2): Akira Togayachi, Kiyohiko Angata, and Shoko Nishihara. Glycan-related genes and genetic disorders. Journal of Human Genetics, Feb 2026. URL: https://doi.org/10.1038/s10038-026-01463-0, doi:10.1038/s10038-026-01463-0. This article has 2 citations and is from a peer-reviewed journal.
(endo2015glycobiologyofαdystroglycan pages 1-2): T. Endo. Glycobiology of α-dystroglycan and muscular dystrophy. Journal of biochemistry, 157 1:1-12, Nov 2015. URL: https://doi.org/10.1093/jb/mvu066, doi:10.1093/jb/mvu066. This article has 190 citations and is from a peer-reviewed journal.
Integrated the FutureHouse Falcon deep-research report (B3GALNT2-deep-research-falcon.md) into the review. The report's conclusions broadly agree with the existing review (core M3 / matriglycan biology, ER-primary localization, avoidance of apoptosis/inflammation/pyroptosis/synaptic over-annotations). Changes made:
reference_review: relevance MEDIUM, correctness VERIFIED. This is the one genuinely new primary paper in the report.supported_by on the IBA Golgi-membrane annotation to back the KEEP_AS_NON_CORE call.description to note the N-glycan/intracellular type-I LacdiNAc activity (kept project-independent, flagged its significance as not yet established) and to state ER-mainly/Golgi-partly localization.suggested_question to reflect that the N-glycan substrate question is now partly addressed by PMID:30898876.Falcon claims NOT acted on (with reasons):
- All other report citations are review/contextual papers (Praissman & Wells 2014, Sheikh 2017, Willer 2014, Endo 2015, Bouchet-Séraphin 2015, Bigotti & Brancaccio 2021, Sharaf-Eldin 2025, Togayachi 2026). They restate known core M3 / matriglycan pathway and disease biology already captured by the existing references and primary citations (PMID:23929950, PMID:23453667, PMID:14724282, Reactome). Adding them as citations would not strengthen any specific annotation; not added.
- Falcon repeatedly frames B3GALNT2 localization as "ER, not primarily Golgi" and at one point implies the Golgi annotation should be downweighted further. The existing review already keeps Golgi as non-core; the Nakane primary data ("mainly ER, partly Golgi") actually justifies retaining the Golgi annotation rather than removing it, so no REMOVE was applied (consistent with not overruling on partial evidence).
- Falcon's muscle/brain/ECM "biological process" discussion describes downstream disease consequences (cobblestone lissencephaly, sarcolemmal integrity, laminin binding). These are organism-level phenotypes of the glycosylation defect, not direct B3GALNT2 GO process functions; no new BP annotations proposed (the review already centers on GO:0035269 O-mannosylation). Consistent with Falcon's own annotation-risk assessment.
- No PMID was added for any claim that could not be resolved/fetched; the only resolvable new primary paper was Nakane 2019.
id: Q8NCR0
gene_symbol: B3GALNT2
product_type: PROTEIN
status: DRAFT
taxon:
id: NCBITaxon:9606
label: Homo sapiens
description: >-
B3GALNT2 is a UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 (EC
2.4.1.313), a type II single-pass membrane glycosyltransferase of the GT31
(beta-1,3-glycosyltransferase) family. It transfers N-acetylgalactosamine
(GalNAc) from UDP-GalNAc in a beta-1,3 linkage onto a terminal beta-linked
N-acetylglucosamine (GlcNAc), producing the disaccharide GalNAc-beta1-3-GlcNAc.
Its principal physiological role is in the elongation of the O-mannosyl glycan
of alpha-dystroglycan (DAG1): acting immediately after POMGNT2 (which adds
beta-1,4-GlcNAc to protein O-mannose), B3GALNT2 caps the chain with beta-1,3-GalNAc
to form the core M3 trisaccharide GalNAc-beta3-GlcNAc-beta4-mannose. This
trisaccharide is the obligate substrate for 6-O-phosphorylation of the mannose
by POMK and for subsequent extension by FKTN, FKRP, RXYLT1, B4GAT1 and LARGE
into matriglycan, the polysaccharide that mediates high-affinity binding of
alpha-dystroglycan to laminin-G domain-containing extracellular matrix proteins.
In addition to this O-mannosyl glycan, B3GALNT2 can synthesize the same
type-I LacdiNAc (GalNAc-beta1,3-GlcNAc) disaccharide on the N-glycans of
mainly intracellular glycoproteins, although the physiological significance of
this broader activity is not yet established. The enzyme is broadly expressed
(highest in testis, adipose, skeletal muscle and ovary) and localizes mainly to
the endoplasmic reticulum and partly to the Golgi apparatus. Biallelic loss-of-function mutations
cause hypoglycosylation of alpha-dystroglycan and a congenital
muscular dystrophy-dystroglycanopathy (MDDGA11), ranging from Walker-Warburg
syndrome to milder muscle-eye-brain phenotypes.
alternative_products:
- name: '1'
id: Q8NCR0-1
- name: '2'
id: Q8NCR0-2
sequence_note: VSP_020250, VSP_020251, VSP_020252
existing_annotations:
- term:
id: GO:0000139
label: Golgi membrane
evidence_type: IBA
original_reference_id: GO_REF:0000033
qualifier: is_active_in
review:
summary: >-
Golgi membrane is the GT31-family default location inferred phylogenetically.
B3GALNT2 is a type II membrane glycosyltransferase and many family members
are Golgi-resident, so this is biologically plausible. However, for the
experimentally characterized alpha-dystroglycan function the enzyme is shown
to act in the endoplasmic reticulum, where O-mannosylation and core M3
assembly occur. Independent glycoproteomic work (Nakane et al. 2019,
PMID:30898876) concurs that B3GALNT2 "mainly localizes in the ER and partly
in the Golgi apparatus", supporting the keep-as-non-core call for the Golgi
membrane location. Keep as a plausible secondary location but not the core
experimentally supported compartment.
action: KEEP_AS_NON_CORE
supported_by:
- reference_id: PMID:30898876
supporting_text: >-
B3GALNT2 mainly localizes in the ER and partly in the Golgi apparatus
- reference_id: file:human/B3GALNT2/B3GALNT2-deep-research-falcon.md
supporting_text: >-
primary experimental evidence more strongly supports ER localization for
active B3GALNT2
- term:
id: GO:0006493
label: protein O-linked glycosylation
evidence_type: IBA
original_reference_id: GO_REF:0000033
qualifier: involved_in
review:
summary: >-
Correct in direction but unspecific. B3GALNT2's characterized biological
role is specifically the elongation of the protein O-mannosyl (core M3)
glycan of alpha-dystroglycan. The more precise child term
"protein O-linked glycosylation via mannose" (GO:0035269) better captures
the actual O-mannosyl pathway rather than generic O-linked (e.g.
mucin-type O-GalNAc) glycosylation.
action: MODIFY
proposed_replacement_terms:
- id: GO:0035269
label: protein O-linked glycosylation via mannose
- term:
id: GO:0008194
label: UDP-glycosyltransferase activity
evidence_type: IBA
original_reference_id: GO_REF:0000033
qualifier: enables
review:
summary: >-
Not wrong (the enzyme uses a UDP-sugar donor) but over-general. The
experimentally established activity is the specific
acetylgalactosaminyltransferase activity (GO:0008376, supported by IDA in
PMID:23929950 and biochemical characterization in PMID:14724282). This
broad parent term should be replaced by the specific activity.
action: MODIFY
proposed_replacement_terms:
- id: GO:0008376
label: acetylgalactosaminyltransferase activity
- term:
id: GO:0000139
label: Golgi membrane
evidence_type: IEA
original_reference_id: GO_REF:0000044
qualifier: located_in
review:
summary: >-
Electronic mapping from the UniProt subcellular-location keyword (Golgi
apparatus membrane, by similarity). Same content as the IBA Golgi
annotation; biologically plausible family default but secondary to the
experimentally supported ER localization for the alpha-DG function.
action: KEEP_AS_NON_CORE
- term:
id: GO:0005783
label: endoplasmic reticulum
evidence_type: IEA
original_reference_id: GO_REF:0000044
qualifier: located_in
review:
summary: >-
Electronic mapping consistent with the experimental IDA localization
(PMID:23453667), where B3GALNT2 was shown to localize to the ER and disease
missense variants perturb this localization. Accept.
action: ACCEPT
- term:
id: GO:0009101
label: glycoprotein biosynthetic process
evidence_type: IEA
original_reference_id: GO_REF:0000120
qualifier: involved_in
review:
summary: >-
Over-general process annotation derived from the InterPro glycosyltransferase
family. B3GALNT2 adds a single GalNAc residue within the alpha-dystroglycan
O-mannosyl glycan; the high-level "glycoprotein biosynthetic process" adds
little specificity over the more informative O-mannosylation term. Replace
with the specific O-mannosylation process term (consistent with the IMP
annotation to the same term).
action: MODIFY
proposed_replacement_terms:
- id: GO:0035269
label: protein O-linked glycosylation via mannose
- term:
id: GO:0016020
label: membrane
evidence_type: IEA
original_reference_id: GO_REF:0000002
qualifier: located_in
review:
summary: >-
Trivial location from the InterPro transmembrane signature. The protein is a
type II single-pass membrane protein, so "membrane" is correct but
uninformative; the specific ER/Golgi membrane terms supersede it.
action: MARK_AS_OVER_ANNOTATED
- term:
id: GO:0016758
label: hexosyltransferase activity
evidence_type: IEA
original_reference_id: GO_REF:0000002
qualifier: enables
review:
summary: >-
Broad InterPro-derived MF term (grandparent of the specific activity). The
enzyme transfers a hexosamine (GalNAc), so the more precise
acetylgalactosaminyltransferase activity (GO:0008376) is the appropriate
term and is experimentally supported.
action: MODIFY
proposed_replacement_terms:
- id: GO:0008376
label: acetylgalactosaminyltransferase activity
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:32296183
qualifier: enables
review:
summary: >-
Generic "protein binding" from a high-throughput binary interactome (Y2H)
screen reporting an interaction with TMBIM1. Per curation guidelines this
term is uninformative about molecular function, and there is no evidence the
TMBIM1 interaction is functionally relevant to the alpha-dystroglycan
glycosylation pathway. Over-annotation; not a core function.
action: MARK_AS_OVER_ANNOTATED
- term:
id: GO:0006493
label: protein O-linked glycosylation
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8932505
qualifier: involved_in
review:
summary: >-
Reactome traceable annotation (DAG1 core M3 glycosylations). Correct
directionally; same generality issue as the IBA O-glycosylation term. The
Reactome pathway is specifically about alpha-DG core M3 O-mannosyl glycan
synthesis, so the more specific O-mannosylation term is preferable.
action: MODIFY
proposed_replacement_terms:
- id: GO:0035269
label: protein O-linked glycosylation via mannose
- term:
id: GO:0008376
label: acetylgalactosaminyltransferase activity
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8931648
qualifier: enables
review:
summary: >-
Correct and specific molecular function from the Reactome reaction
"B3GALNT2 transfers GalNAc to GlcNAc-Man-DAG1". This is the core catalytic
activity of the enzyme. Accept (concordant with the IDA annotation).
action: ACCEPT
- term:
id: GO:0005789
label: endoplasmic reticulum membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8931648
qualifier: located_in
review:
summary: >-
Reactome places the reaction at the ER membrane, consistent with the
experimental ER localization (PMID:23453667) and the fact that the enzyme is
a single-pass ER/Golgi membrane protein acting on the O-mannosyl glycan that
is assembled in the ER. Accept; this is the precise membrane sub-location.
action: ACCEPT
- term:
id: GO:0008376
label: acetylgalactosaminyltransferase activity
evidence_type: IDA
original_reference_id: PMID:23929950
qualifier: enables
review:
summary: >-
Direct experimental demonstration: recombinant B3GALNT2 transfers GalNAc
from UDP-GalNAc onto the GlcNAc-beta4-Man-O-peptide produced by POMGNT2,
forming GalNAc-beta3-GlcNAc-beta4-Man. This is the best-supported molecular
function and the core catalytic activity. Accept.
action: ACCEPT
- term:
id: GO:0006493
label: protein O-linked glycosylation
evidence_type: IDA
original_reference_id: PMID:23929950
qualifier: involved_in
review:
summary: >-
Experimentally supported involvement in O-linked glycosylation via direct
assay on the alpha-DG O-mannosyl glycan. As elsewhere, the more specific
child term "protein O-linked glycosylation via mannose" (GO:0035269) more
precisely reflects the demonstrated O-mannosyl (core M3) elongation.
action: MODIFY
proposed_replacement_terms:
- id: GO:0035269
label: protein O-linked glycosylation via mannose
- term:
id: GO:0005783
label: endoplasmic reticulum
evidence_type: IDA
original_reference_id: PMID:23453667
qualifier: located_in
review:
summary: >-
Direct experimental localization: B3GALNT2 localized to the ER, and disease
missense variants (e.g. G247E, V268M) perturbed this localization. This is
the core, experimentally supported subcellular location for the alpha-DG
function. Accept.
action: ACCEPT
- term:
id: GO:0009101
label: glycoprotein biosynthetic process
evidence_type: IMP
original_reference_id: PMID:23453667
qualifier: involved_in
review:
summary: >-
Mutant-phenotype evidence (patient/zebrafish loss of function causes
alpha-DG hypoglycosylation) does support a role in glycoprotein biosynthesis,
so this is not incorrect. However the term is very general for a single-sugar
transferase; the specific process is O-mannosyl (core M3) glycan elongation
of alpha-dystroglycan. Replace with the specific O-mannosylation process term.
action: MODIFY
proposed_replacement_terms:
- id: GO:0035269
label: protein O-linked glycosylation via mannose
references:
- id: GO_REF:0000002
title: Gene Ontology annotation through association of InterPro records with GO
terms
findings: []
- id: GO_REF:0000033
title: Annotation inferences using phylogenetic trees
findings: []
- id: GO_REF:0000044
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location
vocabulary mapping, accompanied by conservative changes to GO terms applied by
UniProt
findings: []
- id: GO_REF:0000120
title: Combined Automated Annotation using Multiple IEA Methods
findings: []
- id: PMID:14724282
title: A novel human beta1,3-N-acetylgalactosaminyltransferase that synthesizes a
unique carbohydrate structure, GalNAcbeta1-3GlcNAc.
findings:
- statement: >-
Biochemical characterization establishing B3GALNT2 (beta3GalNAc-T2) as a
beta-1,3-N-acetylgalactosaminyltransferase that transfers GalNAc onto
terminal beta-GlcNAc, forming GalNAc-beta1-3-GlcNAc on N- and O-glycans.
supporting_text: >-
Its N-acetylgalactosaminyltransferase activity was observed when
N-acetylglucosamine (GlcNAc) beta1-O-benzyl was used as an acceptor
substrate. The enzyme product was determined to have a beta1,3-linkage by
NMR spectroscopic analysis, and was therefore named
beta1,3-N-acetylgalactosaminyltransferase-II (beta3GalNAc-T2).
reference_review:
relevance: HIGH
correctness: VERIFIED
review_notes: >-
PubMed-verified primary characterization (Hiruma/Narimatsu 2004). Establishes
the strict beta-1,3-GalNAc-T activity and acceptor specificity. Abstract-only
in cache; supporting_text is a verbatim quote from the abstract.
- id: PMID:23453667
title: Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation
of α-dystroglycan.
findings:
- statement: >-
Biallelic B3GALNT2 mutations cause dystroglycanopathy with muscle and brain
involvement via reduced functional glycosylation of alpha-dystroglycan;
B3GALNT2 localizes to the ER and some missense variants perturb this
localization.
supporting_text: >-
B3GALNT2 localized to the endoplasmic reticulum, and this localization was
perturbed by some of the missense mutations identified.
reference_review:
relevance: HIGH
correctness: VERIFIED
review_notes: >-
PubMed-verified. Disease gene identification plus ER localization and
zebrafish knockdown; underpins the IDA (ER) and IMP (glycoprotein biosynthesis)
annotations. Full text available in cache.
- id: PMID:23929950
title: SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan
function.
findings:
- statement: >-
B3GALNT2 acts coordinately with POMGNT2/GTDC2 on protein O-mannose: it
transfers GalNAc onto GlcNAc-beta4-Man to build the core M3 trisaccharide
GalNAc-beta3-GlcNAc-beta4-Man, which is the substrate for POMK
6-O-phosphorylation of the mannose.
supporting_text: >-
MALDI-TOF/MS analysis confirmed that B3GALNT2 could transfer a GalNAc
residue to the acceptor (Fig. 2A), suggesting that B3GALNT2 and GTDC2 can
synthesize GalNAc-β3-GlcNAc-β4-Man.
reference_review:
relevance: HIGH
correctness: VERIFIED
review_notes: >-
PubMed-verified, full text in cache. Directly supports the IDA molecular
function (acetylgalactosaminyltransferase) and the pathway context (core M3,
upstream of POMK phosphorylation and matriglycan).
- id: file:human/B3GALNT2/B3GALNT2-deep-research-falcon.md
title: FutureHouse Falcon deep-research report for B3GALNT2
findings:
- statement: >-
Deep-research synthesis: B3GALNT2 is best supported as an ER glycosyltransferase
acting in the alpha-dystroglycan core M3 O-mannosylation pathway; ER localization
is favoured over Golgi for the active enzyme.
supporting_text: >-
primary experimental evidence more strongly supports ER localization for
active B3GALNT2
reference_review:
relevance: MEDIUM
correctness: VERIFIED
review_notes: >-
FutureHouse Falcon deep-research report. Conclusions concordant with the
curated review; its one novel primary citation (Nakane 2019) was resolved to
PMID:30898876 and added separately. Used here only to anchor the
localization synthesis; substantive claims are cited to primary papers.
- id: PMID:30898876
title: Identification of mammalian glycoproteins with type-I LacdiNAc structures
synthesized by the glycosyltransferase B3GALNT2.
findings:
- statement: >-
Beyond the alpha-dystroglycan O-mannosyl glycan, B3GALNT2 also synthesizes
type-I LacdiNAc (GalNAc-beta1,3-GlcNAc) on the N-glycans of mainly
intracellular glycoproteins (e.g. LRP1 and nicastrin), demonstrating a
broader acceptor scope than alpha-DG alone.
supporting_text: >-
Our results further revealed that LDN presence on low-density lipoprotein
receptor-related protein 1 and nicastrin depends on B3GALNT2, indicating
the occurrence of type-I LDN in vivo in mammalian cells.
- statement: >-
B3GALNT2 preferentially modifies intracellular (especially ER-resident)
glycoproteins, in contrast to the Golgi-resident type-II LDN synthases
B4GALNT3/B4GALNT4 that act on extracellular glycoproteins.
supporting_text: >-
B3GALNT2 primarily transferred LDN to intracellular glycoproteins, thereby
clearly delineating proteins that carry type-I or type-II LDNs.
- statement: >-
Independent localization evidence: B3GALNT2 mainly localizes to the ER and
partly to the Golgi apparatus, reconciling the experimentally supported ER
location with the family-default Golgi annotation.
supporting_text: >-
B3GALNT2 mainly localizes in the ER and partly in the Golgi apparatus
reference_review:
relevance: MEDIUM
correctness: VERIFIED
review_notes: >-
PubMed-verified primary glycoproteomics study (Nakane et al. 2019, JBC),
full text in cache. Establishes that B3GALNT2 makes type-I LacdiNAc on
N-glycans of intracellular/ER glycoproteins (LRP1, nicastrin) beyond the
alpha-DG O-mannosyl glycan, and provides independent evidence that the
enzyme is mainly ER- and partly Golgi-localized. Relevant to substrate
scope and the ER vs Golgi localization question, but the in-vivo
significance of the N-glycan activity is not yet established, so MEDIUM.
- id: PMID:32296183
title: A reference map of the human binary protein interactome.
findings:
- statement: >-
High-throughput binary (Y2H) interactome reporting a B3GALNT2-TMBIM1
interaction; basis of the generic "protein binding" IPI annotation.
supporting_text: >-
A reference map of the human binary protein interactome.
reference_review:
relevance: LOW
correctness: VERIFIED
review_notes: >-
PubMed-verified large-scale interactome (HuRI). The single binary
interaction (TMBIM1) is not informative of catalytic function and has no
established link to the alpha-DG pathway; supports only a generic protein
binding annotation.
- id: Reactome:R-HSA-8931648
title: B3GALNT2 transfers GalNAc to GlcNAc-Man-DAG1
findings:
- statement: >-
Reactome reaction modeling the ER-membrane-associated transfer of GalNAc by
B3GALNT2 onto GlcNAc-Man-DAG1 during alpha-dystroglycan core M3 synthesis.
supporting_text: >-
ER membrane-associated UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase
2 (B3GALNT2) transfers N-acetylgalactosamine (GalNAc) from UDP-GalNAc to
GlcNAc-Man-DAG1 via a 1-3 glycosidic bond
reference_review:
relevance: HIGH
correctness: VERIFIED
review_notes: >-
Reactome reaction consistent with the experimental literature; basis for the
TAS MF (acetylgalactosaminyltransferase) and ER membrane location annotations.
- id: Reactome:R-HSA-8932505
title: DAG1 core M3 glycosylations
findings:
- statement: >-
Reactome pathway for alpha-dystroglycan core M3 O-mannosyl glycan synthesis,
within which B3GALNT2 acts; basis of the TAS O-linked glycosylation process
annotation.
supporting_text: DAG1 core M3 glycosylations
reference_review:
relevance: HIGH
correctness: VERIFIED
review_notes: >-
Pathway-level Reactome annotation placing B3GALNT2 in the alpha-DG core M3
O-mannosylation pathway.
core_functions:
- description: >-
B3GALNT2 catalyzes transfer of N-acetylgalactosamine from UDP-GalNAc in a
beta-1,3 linkage onto the terminal beta-1,4-GlcNAc of the protein O-mannosyl
glycan of alpha-dystroglycan (added by POMGNT2), forming the core M3
trisaccharide GalNAc-beta3-GlcNAc-beta4-Man. This step is required for
subsequent POMK-dependent 6-O-phosphorylation of the mannose and downstream
matriglycan extension, and hence for functional glycosylation of
alpha-dystroglycan and its high-affinity binding to laminin-G domain ECM
ligands. The enzyme acts as a single-pass type II membrane protein in the ER.
molecular_function:
id: GO:0008376
label: acetylgalactosaminyltransferase activity
directly_involved_in:
- id: GO:0035269
label: protein O-linked glycosylation via mannose
locations:
- id: GO:0005783
label: endoplasmic reticulum
- id: GO:0005789
label: endoplasmic reticulum membrane
substrates:
- id: CHEBI:67138
label: UDP-N-acetyl-alpha-D-galactosamine
supported_by:
- reference_id: PMID:23929950
supporting_text: >-
MALDI-TOF/MS analysis confirmed that B3GALNT2 could transfer a GalNAc
residue to the acceptor (Fig. 2A), suggesting that B3GALNT2 and GTDC2 can
synthesize GalNAc-β3-GlcNAc-β4-Man.
- reference_id: PMID:14724282
supporting_text: >-
The enzyme product was determined to have a beta1,3-linkage by NMR
spectroscopic analysis, and was therefore named
beta1,3-N-acetylgalactosaminyltransferase-II (beta3GalNAc-T2).
- reference_id: PMID:23453667
supporting_text: >-
B3GALNT2 localized to the endoplasmic reticulum, and this localization was
perturbed by some of the missense mutations identified.
proposed_new_terms:
- proposed_name: protein O-mannose beta-1,3-N-acetylgalactosaminyltransferase activity
proposed_definition: >-
Catalysis of the transfer of an N-acetylgalactosaminyl residue from
UDP-N-acetyl-D-galactosamine to the 3-position of the beta-1,4-linked
N-acetylglucosamine of a protein O-linked mannosyl glycan, forming a
beta-1,3 glycosidic bond and producing the
GalNAc-beta1,3-GlcNAc-beta1,4-mannose (core M3) trisaccharide. EC 2.4.1.313.
justification: >-
The existing MF term GO:0008376 (acetylgalactosaminyltransferase activity) is
defined as transfer of GalNAc to an oligosaccharide and is broader than the
physiologically relevant reaction. There is no GO term specific to the
protein-O-mannose-glycan acceptor / EC 2.4.1.313 reaction that B3GALNT2
performs in alpha-dystroglycan core M3 biosynthesis (a gap flagged by the
RHEA-GO project). A child of GO:0008376 grounded on RHEA:37667 / EC 2.4.1.313
would let B3GALNT2 be annotated to its exact catalytic activity.
proposed_parent:
id: GO:0008376
label: acetylgalactosaminyltransferase activity
proposed_mappings:
- predicate: skos:exactMatch
target_term:
id: RHEA:37667
label: 3-O-(GlcNAc-(1->4)-Man)-Thr-[protein] + UDP-GalNAc = core M3 trisaccharide-Thr-[protein] + UDP + H(+)
- predicate: skos:exactMatch
target_term:
id: EC:2.4.1.313
label: protein O-mannose beta-1,3-N-acetylgalactosaminyltransferase
suggested_questions:
- question: >-
Besides alpha-dystroglycan, are there other physiological protein substrates
that carry the GalNAc-beta3-GlcNAc-beta4-Man (core M3) structure built by
B3GALNT2 in vivo?
- question: >-
Is B3GALNT2 active in the ER, the Golgi, or both for the alpha-DG pathway, and
does its compartmentalization differ from canonical Golgi GT31 family members?
- question: >-
Does the in vitro activity toward N-glycan and core-2 O-GalNAc acceptors
(reported in the original characterization) reflect any biological function,
or is the O-mannosyl core M3 its sole in vivo role? Glycoproteomics
(PMID:30898876) shows B3GALNT2-dependent type-I LacdiNAc on N-glycans of
intracellular/ER glycoproteins (e.g. LRP1, nicastrin), but the physiological
significance of these N-glycan modifications is not yet established.
suggested_experiments:
- description: >-
Glycoproteomic / mass-spectrometric profiling of alpha-dystroglycan and the
broader glycoproteome in B3GALNT2-knockout versus wild-type cells to confirm
loss of the GalNAc-beta3-GlcNAc-beta4-Man core M3 structure and to identify
any additional core-M3-bearing substrates.
- description: >-
In vitro reconstitution of the POMGNT2 -> B3GALNT2 -> POMK reaction sequence
with defined glycopeptide acceptors to quantify B3GALNT2 kinetics on the
physiological O-mannosyl acceptor and confirm strict dependence of POMK
phosphorylation on prior B3GALNT2 action.
- description: >-
Structure-function analysis of MDDGA11 missense variants (e.g. G247E, V268M,
R292P) measuring catalytic activity, ER retention/localization, and protein
stability to dissect how each impairs alpha-DG glycosylation.